Long-Term Immunotherapy Benefits For Melanoma Shown in Ten-Year Survival Data
Two medications have been shown to drastically alter the prognosis for the fatal skin disease melanoma, according to information gained through a decade of follow-up on patients receiving cancer...
View ArticleBiogen and UCB’s lupus drug achieves primary objective in late-stage trial
Biogen and UCB have published a listing of a late-stage clinical trial of dapirolizumab pegol, an experimental drug for treating lupus, a disease in development for over twenty years. The drug, when...
View ArticleExperimental Pill by Novo Nordisk Shown to Have Side Effects in Trial
Amycretin, Novo Nordisk’s much-anticipated experimental weight-loss drug, was found to be safe in an early-stage trial, with mild to moderate side effects, the company reported on Wednesday. In March,...
View ArticleVicebio Raises $100 Million in Series B Funding to Advance RSV Combination...
Vicebio, the British biotech, has closed a $100 million Series B funding round as it advances a Phase I study of its bivalent vaccine for RSV and human metapneumovirus (hMPV). A readout for the...
View ArticlePicnicHealth Launches New Service Bringing Observational Clinical Trials to...
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted at observational research...
View ArticleFDA authorizes the first novel schizophrenia therapy in decades
The FDA gave the green light to Bristol Myers Squibb’s much-anticipated schizophrenia drug Cobenfy, the first new chemical entity to treat the severe, chronic mental illness in more than 70 years....
View ArticleAstraZeneca Expands AI-Powered Immuno-Oncology Research Partnership with Immunai
Immunai, a biotechnology company based in New York, has partnered with AstraZeneca in a multiyear endeavor to try and change the cancer immunotherapy trials through AI. This partnership will utilize...
View ArticleAbbVie’s Parkinson’s Drug Meets Phase 3 Trial Goal
AbbVie has disclosed that its late-stage monotherapy prospect substantially decreased the impact of the condition in patients as contrasted with placebo on the same day that various medications used in...
View ArticleRepair Biotechnologies to Leverage Genevant Sciences’ LNP Technology for...
Repair Biotechnologies has joined forces with Swiss company Genevant Sciences to gain access to Genevant’s lipid nanoparticle (LNP) technology delivery system. Repair will specifically use this...
View ArticleEditas Sells Rights to a Licensing Agreement in a $57 Million Deal
In a recent move, Editas sold part of these rights to DRI Healthcare’s subsidiary, a healthcare royalties company. The transaction will generate $57 million for Editas upon closing. In exchange, Editas...
View ArticleScholar Rock’s Phase 3 SMA Trial Achieves Success
Scholar Rock Inc has announced that the phase 3 trial of Apitegromab for spinal muscular atrophy treatment has come through with its primary result. Despite this, the higher dosage did not achieve the...
View ArticleJ&J Halts Late-Stage Trial For Bladder Cancer Prospect
Johnson & Johnson’s SunRISe-2 study has officially been discontinued. Johnson & Johnson terminated the phase 3 bladder cancer study after an interim analysis indicating that the TAR-200...
View ArticleDevelopments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which played a pivotal role in controlling the COVID-19...
View ArticleTalk of vaccine schedule revision amidst research showing waning efficacy of...
A large phase 3 study conducted over GSK’s RSV vaccine Arexvy has shown how the vaccine’s efficacy varies and wanes over seasons. The study enrolled around 25,0000 people from 17 different countries...
View ArticleMaven Clinic receives $125 million to fund technology and value-based treatment
Maven Clinic, an online clinic for women and family health, has closed its series F funding round at $125 million. StepStone Group led the round, and General Catalyst, Sequoia, Oak HC/FT, Icon...
View ArticleThe medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller and Mike Baird of Schlafender Hase...
View ArticleLife Sciences Voice Top Five Newsletter
Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the latest news in the life sciences industry! This week, we take a look at BMS gaining approval for its...
View ArticleNew drug Roche to enter breast cancer therapy field
The Food and Drug Administration (FDA) has recently granted approval to Swiss company Roche’s inavolisib for treating HR-positive, HER2-negative breast cancer. The treatment has been approved for...
View ArticleWisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care vertical is marketed as a...
View ArticleNovartis strikes $1.1B deal with China’s Baiyu for a small molecule cancer...
Novartis is investing over $70 million in Chengdu Baiyu Pharmaceutical to bolster its roster of cancer therapy prospects. It recently struck a $1.1 billion deal which includes milestones for a small...
View Article